中药注射液防治化疗相关心脏毒性的系统评价再评价

doi:10.20047/j.issn1673-7210.2023.29.32

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1019 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To evaluate the quality of report, methodological quality, and evidence level of systematic review on the prevention and treatment of chemotherapy-related cardiotoxicity by traditional Chinese medicine injection. Methods The PubMed, EMBase, Cochrane Library, CNKI, VIP, Wanfang Data, China Biomedical Literature Service System database were searched, the time limited to the database establishment until April 31, 2022. The published articles on systematic reviews/meta-analyses of traditional Chinese medicine injection for the prevention and treatment of chemotherapy-related cardiotoxicity were collected. The PRISMA statement was used to evaluate the reporting quality of the included studies, the AMSTAR2 scale and the GRADE rating system were used to evaluate the methodological quality and the level of evidence. Results A total of nine articles were included, and PRISMA scores ranged from 13.5 to 23 points. There were shortcomings in scheme and registration, other analysis and funding sources. AMSTAR2 evaluation indicated that the quality rating of one article was very low, three articles were low, and five articles were intermediate. GRADE Evidence quality was graded from medium quality to very low quality. A total of 49 outcome indicators were included, of which 11 were of medium quality, 10 were of low quality, and 28 were of very low quality. Conclusion The existing evidence suggests that the systematic evaluation methodology and evidence quality of traditional Chinese medicine injection for prevention and treatment of chemotherapy-related cardiotoxicity are low, but the efficacy is positive. Compared with the use of chemotherapy drugs alone or placebo, the incidence of electrocardiogram abnormalities and left ventricular ejection fraction of the main outcome indicators suggest that traditional Chinese medicine injection can effectively improve the prevention and treatment of chemotherapy-related cardiotoxicity.

Key words： Chinese medicine injection Chemotherapy Cardiotoxicity Systematic review Meta-analysis System evaluation re-evaluation

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Mengdi1 PU Dongqing1 SHI Guangxi1 LI Jingwei2

Cite this article:

ZHANG Mengdi1 PU Dongqing1 SHI Guangxi1 LI Jingwei2. A reevaluation on systematic review of chinese medicine injection for the prevention and treatment of chemotherapy-related cardiotoxicity[J]. 中国医药导报, 2023, 20(29): 144-151.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.29.32 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I29/144

[1] McGowan JV，Chung R，Maulik A，et al. Anthracycline Chem- otherapy and Cardiotoxicity [J]. Cardiovasc Drugs Ther，2017， 31（1）：63-75.
[2] 张剑辉，回天立，栾士超，等.化疗相关化疗药物治疗乳腺癌的毒性及其防治[J].实用癌症杂志，2015，30（7）：1041- 1043.
[3] 高晓丽，李妙龄.抗肿瘤药的心脏毒性[J].西南医科大学学报，2019，42（5）：483-488.
[4] 周瑶，鲍翠玉，李晶.蒽环类药物相关心脏毒性的发病机制及治疗研究进展[J].湖北科技学院学报（医学版），2019， 33（6）：547-549.
[5] 田钰，高举.蒽环类药物相关心脏毒性的发病机制和诊治进展[J].国际输血及血液学杂志，2019，4（8）：351-357.
[6] 胡楠，贺白，徐姗，等.蒽环类药物心脏毒性相关代谢酶和转运体基因多态性的研究进展[J].中南药学，2020，18（6）：1031-1037.
[7] 盛男.抗肿瘤药紫杉醇注射治疗患者的不良反应发生情况分析[J].中国当代医药，2022，29（7）：115-117，121.
[8] 李田宏.化疗相关药物所致心脏毒性与中医证型相关性及中药防治的临床研究[D].沈阳：辽宁中医药大学，2019.
[9] Cook DJ，Mulrow CD，Haynes RB. Systematic reviews：synthesis of best evidence for clinical decisions [J]. Ann Intern Med，1997，126（5）：376-380.
[10] 杨克虎，刘雅莉，袁金秋，等.发展和完善中的系统评价再评价[J].中国循证儿科杂志，2011，6（1）：54-57.
[11] Liberati A，Altman DG，Tetzlaff J，et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions：explanation and elaboration [J]. PLoS Med，2009，6（7）：e1000100.
[12] 陶欢，杨乐天，平安，等.随机或非随机防治性研究系统评价的质量评价工具AMSTAR 2解读[J].中国循证医学杂志，2018，18（1）：101-108.
[13] Shea BJ，Reeves BC，Wells G，et al. AMSTAR 2：a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions，or both [J]. BMJ，2017，358：j4008.
[14] 曾宪涛，冷卫东，李胜，等.如何正确理解及使用GRADE系统[J].中国循证医学杂志，2011，11（9）：985-990.
[15] 杨敏，卢静，牟金金，等.生脉注射液防治化疗相关抗肿瘤药心脏毒性的系统评价[J].中国药物警戒，2012，9（11）：666-669.
[16] 隆耀莹，徐柳月，唐晓琼，等.参芪扶正注射液防治化疗相关药物心脏毒性的Meta分析[J].检验医学与临床，2019， 16（11）：1550-1554.
[17] 马腾，朱明军，王永霞，等.心脉隆注射液治疗化疗相关药物化疗后心脏毒性的Meta分析[J].中药新药与临床药理，2021，32（6）：886-893.
[18] 马腾，朱明军，王永霞，等.参麦注射液联合右丙亚胺防治化疗相关药物心脏毒性的Meta分析及GRADE评价[J].中医杂志，2021，62（18）：1598-1605.
[19] 万光升，刘丽丽，李敬瑜，等.参麦注射液预防化疗所致心脏毒性的系统评价[J].中西医结合心脑血管病杂志，2017，15（8）：904-910.
[20] 张金华，吴超君，蔡刚，等.参麦注射液防治恶性肿瘤化疗所致心脏毒性系统评价[J].中国中医药信息杂志，2018，25（9）：96-100.
[21] 刘杰，罗莉，杨柱，等.参芪扶正注射液防治化疗相关心脏毒性的Meta分析[J].中医肿瘤学杂志，2021，3（1）：82- 89.
[22] 于瑞，王建茹，彭广操，等.中药注射液防治化疗相关药物所致心脏毒性的系统评价[J].中草药，2021，52（10）：3051-3060.
[23] 张方圆，沈傲梅，曾宪涛，等.系统评价方法学质量评价工具AMSTAR 2解读[J].中国循证心血管医学杂志，2018， 10（1）：14-18.
[24] Zhang L，Zhang J，Chen J，et al. Clinical research of traditional chinese medicine needs to develop its own system of core outcome sets [J]. Evid Based Complement Alternat Med，2013，2013：202703.
[25] 蔡英敏，胡海涛，马小亚，等.参芪扶正注射液对老龄大鼠脑缺血再灌注损伤的保护作用[J].中国中医药现代远程教育，2014，12（7）：147-149.
[26] 马增春，肖勇，赵佳伟，等.人参皂苷Re对H9c2心肌细胞CYP450酶的影响[J].中国药理学通报，2016，32（4）：494-498.
[27] 李靳，邓丽丽，周志勇，等.三七总皂苷联合淫羊藿总黄酮改善D-gal致H9c2大鼠心肌细胞衰老的保护作用[J].中国中药杂志，2017，42（3）：555-561.
[28] 汪艳群，孟宪军.超声波处理对北五味子多糖抗氧化活性的影响[J].食品科学，2016，37（3）：66-70.
[29] 姜金龙，计成阜，何广胜，等.生脉注射液结合持续静脉缓慢滴注蒽环类药物降低早期心脏毒性发生风险的临床观察[J].现代肿瘤医学，2021，29（3）：499-502.